Nippon Shinyaku Licenses Once-daily Tramadol From Labopharm
This article was originally published in PharmAsia News
Executive Summary
Kyoto-based Nippon Shinyaku and Canadian Labopharm entered into a license agreement under which Nippon Shinyaku obtained exclusive development, marketing and distribution rights in Japan for once-daily tramadol sustained-release tablet